title: Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?
authors: D J
authors: DJ
authors: Rosario
authors: L
authors: L
authors: Bourke
mesh_terms: D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal
references: Lancet Oncol. 2013 Apr;14(4):306-16
references: 23465742
references: Br J Cancer. 2013 May 28;108(10):2192-3
references: 23632479